Page 3 - Pharmaceutical Firms

Jefferies upbeat on India CRDMO; initiates Buy on Cohance; upgrades Divi's

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details

Aurobindo Pharma leads $5 billion race to acquire Prague-based Zentiva

Shortly after reports of the potential acquisition surfaced, Aurobindo clarified that no binding agreement or definitive decision has been made regarding the deal

Pharma Inc mulls offshore strategy as US tariff fears hit sentiment

Despite current exemptions, Indian pharma firms are preparing for potential US tariffs through offshore units, EU market focus, and sourcing diversification

Indian pharma market grows 7.9% in July, led by chronic therapies

Despite flat volumes, India's pharma market posted 7.9% growth in July on strong demand for chronic therapies like cardiac and diabetes; MAT turnover crossed Rs 2.3 trillion

Lupin shares advance 5% after Q1 results; should you buy in?

Lupin shares rose 5 per cent after the firm posted a 52 per cent year-on-year increase in net profit in Q1 FY26

Emcure Pharma shares gain as JM Financial initiates coverage; check target

JM Financial initiated coverage on Emcure Pharma with a 'Buy' rating and a target price of ₹1,740, citing its growth prospects

India launches formal rules to fix, streamline drug and device clearances

India has issued first official guidelines for expert panels to bring consistency, speed, and transparency to drug and device approvals amid a broader regulatory overhaul

Trump tariff on Indian goods to raise drugs costs in US: Pharmexcil

Pharmaceuticals Export Promotion Council of India (Pharmexcil) on Thursday said President Donald Trump's imposition of a 25 per cent tariff plus unspecified penalty on all goods coming from India starting August 1, will result in increased costs for essential drugs in the US, ultimately harming consumers and healthcare systems in the country in the long term. The US market, heavily reliant on India for Active Pharmaceutical Ingredients (APIs) and low-cost generics, faces a daunting challenge in finding alternative sources that can match the scale, quality, and affordability that India offers, Pharmexcil Chairman Namit Joshi said in a statement. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Reacting to the development, Joshi said India has long been a cornerstone of the global supply chain for affordable, high-qualit

US CDMO business seeing softening, says Piramal Pharma Chairperson

US biotech funding slowdown hits Piramal's CDMO business as company expands sterile injectables facility and maintains long-term growth targets

Torrent Pharma Q1 results: PAT up 20% on robust sales across territories

Torrent Pharmaceuticals reports Rs 548 crore Q1 net profit, led by strong growth in India, the US, and Brazil, with chronic therapies and top brands driving momentum

Results preview: Pharma firms stare at muted earnings growth for Q1

Indian pharma firms are set to post modest Q1FY26 earnings, with Revlimid erosion impacting US revenues and domestic growth moderating in chronic therapies

Blue Jet Healthcare shares drop 10% post Q1 results; details here

At 2:30 PM, shares of Blue Jet Healthcare were trading at ₹906.15, down by 10 per cent on the BSE.

Sun Pharma's psoriasis drug delivers positive results in arthritis trials

Phase 3 trials show ILUMYA improved PsA symptoms significantly, with no new safety concerns; results support potential regulatory submissions in the US and globally

CORONA Remedies acquires 7 pharma brands from Bayer India, plans expansion

CORONA Remedies deepens footprint in women's healthcare and cardiology with Bayer India portfolio acquisition, entering anti-platelet and hormone therapy segments

CDSCO extends COPP application deadline for pharma units to August 15

Pharma firms get time till August 15 to file COPP applications online via ONDLS as CDSCO addresses onboarding challenges and industry pleas

PL Capital bets on domestic sectors, sees 6.5% Nifty growth in 12 months

PL Capital expects pharma, banks, defence, and staples to outperform in the near term as domestic demand revives

Generic glut leads to numerous price actions on diabetes medications

Government may fix retail prices for empagliflozin combinations as generic versions flood the market following the drug's patent expiry, causing price drops

Sun Pharma gains on US launch of Leqselvi, analysts see strong upside

Sun Pharma rises 2.7% as it launches Leqselvi in US following settlement with Incyte, with analysts projecting $200-300 million revenue from the drug in 3-5 years

Sun Pharma shares rise 2% on US launch of hair loss drug after settlement

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia areata

Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp

Sun Pharma will pay Incyte an upfront fee and royalties to market Leqselvi in the US for alopecia areata until patent expiry in FY26 following a litigation settlement